Welcome to AiCuris: The Powerhouse for Anti-Infectives

AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.

 

 

 

Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

Positive CHMP opinion

 

AiCuris’ Licensee MSD Received Positive CHMP Opinion for PREVYMIS™ (Letermovir) Recommending Approval in Europe

  • Just after U.S. market approval
  • MSD anticipates that European Commission decision will be adopted within approx. 2 months

Read more ...

Drug from AiCuris approved

 

AiCuris’ Licensee MSD Received U.S. FDA Approval of PREVYMIS™ (Letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients

  • First antiviral drug developed from AiCuris’ pipeline to receive market approval
  • PREVYMIS is the first new medicine for CMV infection approved in the U.S. in 15 years
  • AiCuris to receive milestone payments and royalties on sales

Read more ...

AIC649 data presented at AASLD

 

AiCuris AIC649 Showed Potential for Functional Cure in Woodchuck Model for Chronic Hepatitis B

  • AIC649 showed to induce a physiologically concerted, reconstituted immune response in the woodchuck model for chronic hepatitis B
  • Sustained loss of Woodchuck Hepatitis virus surface antigen (WHsAg) and induction of anti-WHsAg antibodies observed
  • In combination with standard of care entecavir (ETV) AIC649 dramatically increases efficacy of treatment

Read more ...